Wugen Raises $172m To Advance NK Cells In Blood Cancers, Solid Tumors
Lead Program Being Tested In AML, Moving Into Other Cancers
Executive Summary
Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials.